Sukhmani Kaur Padda | Temple Health

Dr. Sukhmani Padda, MD

Claim this profile

Cedars Sinai Medical Center

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
7 reported clinical trials
12 drugs studied

Area of expertise

1Lung Cancer
Sukhmani Padda, MD has run 6 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
EGFR positive
Stage III
2Non-Small Cell Lung Cancer
Sukhmani Padda, MD has run 4 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage IV
EGFR positive
ALK positive

Affiliated Hospitals

Image of trial facility.
Cedars-Sinai Medical Center
Image of trial facility.
Torrance Memorial Physician Network / Cancer Care

Clinical Trials Sukhmani Padda, MD is currently running

Image of trial facility.

Bevacizumab + Chemoimmunotherapy + Atezolizumab

for Small Cell Lung Cancer

This clinical trial aims to assess whether the addition of bevacizumab to atezolizumab and chemotherapy can improve response to treatment and progression-free survival in patients with extensive-stage small cell lung cancer (ES-SCLC) with liver metastases. The main questions it aims to answer are: * In patients with ES-SCLC with liver metastases, can bevacizumab in combination with atezolizumab and chemotherapy prolong the length of time that the cancer does not progress? * Is bevacizumab safe and tolerable when combined with atezolizumab and chemotherapy in patients with ES-SCLC and liver metastases? The study treatment includes two phases: * Induction phase: bevacizumab will be administered in combination with atezolizumab and chemotherapy on a 21-day cycle for four cycles. * Maintenance: atezolizumab and bevacizumab will be administered every 21 days for up to 12 months, or until unacceptable toxicity or disease progression. Participants will undergo blood tests every 3 weeks and tumor assessments every 6 weeks.
Recruiting1 award Phase 211 criteria
Image of trial facility.

Lutetium Lu 177 Dotatate

for Lung Carcinoid Tumor

This trial studies the effect of lutetium Lu 177 dotatate in patients with advanced bronchial neuroendocrine tumors. Lutetium Lu 177 dotatate targets cancer cells with radiation, aiming to kill or shrink them while sparing healthy cells. The goal is to see if it works better than the usual treatment. Everolimus has been shown to help patients with various types of neuroendocrine tumors.
Recruiting1 award Phase 210 criteria

More about Sukhmani Padda, MD

Clinical Trial Related8 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Sukhmani Padda, MD has experience with
  • Sotorasib
  • Necitumumab
  • Afatinib
  • Nab-paclitaxel
  • ORIC-101
  • CAB-AXL-ADC

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Sukhmani Padda, MD specialize in?
Is Sukhmani Padda, MD currently recruiting for clinical trials?
Are there any treatments that Sukhmani Padda, MD has studied deeply?
What is the best way to schedule an appointment with Sukhmani Padda, MD?
What is the office address of Sukhmani Padda, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security